A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of single-agent AT-101 in men with hormone-refractory prostate cancer.
Hormone Refractory Prostate Cancer
DRUG: AT-101
Number of participants with adverse events.
Complete or partial remission of disease
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of single-agent AT-101 in men with hormone-refractory prostate cancer.